Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Lithium cation
Drug ID BADD_D01304
Description Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
Indications and Usage Lithium, in its salt forms, is used as a mood stabilizer and for the treatment of depression and mania. It is most frequently prescribed in the treatment of bipolar disorder.
Marketing Status experimental
ATC Code N05AN01
DrugBank ID DB01356
KEGG ID D08133
MeSH ID D008094
PubChem ID 28486
TTD Drug ID D5MF8Y
NDC Product Code Not Available
UNII 8H8Z5UER66
Synonyms Lithium | Lithium-7 | Lithium 7
Chemical Information
Molecular Formula Li+
CAS Registry Number 17341-24-1
SMILES [Li+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Musculoskeletal discomfort15.03.04.001--Not Available
Affect lability19.04.01.0010.000192%Not Available
Cerebral disorder17.02.10.0170.000192%Not Available
Dysphemia17.02.08.010; 19.19.03.0050.000288%Not Available
Bipolar disorder19.16.01.0030.000998%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.001901%
Metabolic disorder14.11.01.0010.000192%Not Available
Brugada syndrome03.07.07.004; 02.03.02.033--Not Available
Urine output increased13.13.03.002--Not Available
Electrocardiogram change13.14.05.014--Not Available
Mental disorder19.07.01.0020.000576%Not Available
Mental disorder due to a general medical condition19.07.03.005--Not Available
Abnormal behaviour19.01.01.0010.000576%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Renal injury20.01.03.015; 12.01.05.0010.000576%Not Available
Renal neoplasm20.01.04.004; 16.08.03.0010.000192%Not Available
Parkinson's disease17.01.05.0100.000192%Not Available
Adverse drug reaction08.06.01.0090.000576%Not Available
Disease recurrence08.01.03.0500.000384%Not Available
Psychotic disorder19.03.01.0020.000672%
Renal impairment20.01.03.0100.001287%Not Available
Unevaluable event08.01.03.0510.000480%Not Available
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.000480%Not Available
Autism spectrum disorder17.03.05.003; 19.22.02.0020.000192%Not Available
Chronic kidney disease20.01.03.0170.004455%
Bone marrow failure01.03.03.0050.000288%
Treatment failure08.06.01.0170.002035%Not Available
Renal cell carcinoma20.01.04.003; 16.08.02.0020.000576%Not Available
Acute kidney injury20.01.03.0160.007143%
The 9th Page    First    Pre   9 10 11    Next   Last    Total 11 Pages